Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 460 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban February 7, 2022 6 of the biggest good news cancer stories of 2021 December 15, 2021 Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... October 1, 2024 Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Load more HOT NEWS Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... The most important cancer research stories of 2022 Καρκίνος Δέρματος Medicare Advantage Plans: Read the Fine Print
